In a study on prostate cancer, it was proven that CAPE treatment suppresses the migration and invasion of PC-3 and DU-145 PCa cells via the elevation of ROR2 (tyrosine-kinase-like orphan receptor 2) and E-cadherin proteins and via the reduction in vimentin protein [59]. This evidence concerns the gene VIM and prostate carcinoma.